Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT05709626

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

Conditions: ST-segment Elevation Myocardial Infarction (STEMI)

Sex: All

Ages: 18 Years – N/A

Phase: PHASE4

Enrollment: 2258

Sponsor: Kindai University

Summary

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

Eligibility Criteria

Inclusion Criteria:Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)STEMI patientsPatients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 monthsExclusion Criteria:Patients taking anticoagulantsPatients under 18 years oldPatients with less than 1 year prognosisPatients participating in other intervention studies

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05709626). StuddyBuddy aggregates publicly available trial information.